Ключевые слова
Как цитировать
Аннотация
В настоящее время рак шейки матки (РШМ) является одним из основных социально значимых онкологических заболеваний у женщин различных возрастных групп. При этом сопутствующая химиолучевая терапия с последующей лучевой и автоматизированной брахитерапией является стандартным методом лечения, в первую очередь, местнораспространенного рака шейки матки (МРРШМ), со стадиями заболевания от IB3 до IVA по FIGO, и которая является весьма эффективным терапевтическим методом противоопухолевого лечения для многих пациенток. Следует подчеркнуть, что за последние два десятилетия был достигнут значительный прогресс в лечении РШМ, особенно в области радикальной химиолучевой терапии местно-распространенного рака шейки матки. При этом парадигмы лучевой терапии (ЛТ) перешли от двухмерного (2D) подхода, основанного исключительно на анатомических костных ориентирах, к трехмерному (3D) подходу с визуальным контролем за процессом проведения лучевой терапии, позволяющему доставлять увеличенные очаговые дозы облучения более точно к клиническим мишеням с максимальным сохранением органов риска. В данном кратком обзоре обсуждаются текущие достижения в области противоопухолевого лечения инвазивного МРРШМ с акцентом на визуализацию лечебного процесса (лучевой терапии и автоматизированной брахитерапии) при применении адъювантной и неоадъювантной химиотерапии и радикальной одновременной химиолучевой терапии. Особое внимание уделяется текущим достижениям и будущим направлениям исследований в области лучевой терапии (ЛТ) с упором на трехмерную брахитерапию, ЛТ с модулированной интенсивностью под визуальным контролем, а также протонную ЛТ и иммунотерапию при одновременной химиолучевой терапии.
Библиографические ссылки
Солодкий В.А., Титова В.А., Паньшин Г.А. Эволюционное развитие технологий лучевой терапии местнораспространенного рака шейки матки. Вопросы онкологии, 2023;69(1):15-23 [Solodkiy VA, Titova VA, Panshin GA. Evolutionary development of radiotherapy technologies in locally advanced cervical cancer. Voprosy Onkologii. 2023;69(1):15-23 (In Russ.)]. https://doi.org/10.37469/0507-3758-2023-69-1-15-23.
Zhao M, Wu Q, Hao Y, et al. Global, regional, and national burden of cervical cancer for 195 countries and territories, 2007-2017: findings from the Global Burden of Disease Study 2017. BMC Womens Health. 2021;21(1):419. https://doi.org/10.1186/s12905-021-01571-3.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660.
Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:239 [Kaprin AD, Starinsky VV, Shakhzadova AO, eds. State of oncological care for the Russian population in 2021. Moscow: P.A. Herzen Moscow State Medical Research Institute − Branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia. 2022:239 (In Russ.)].
Berek JS, Matsuo K, Grubbs BH, et al. Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. J Gynecol Oncol. 2019;30(2):e40. https://doi.org/10.3802/jgo.2019.30.e40.
Benard VB, Watson M, Saraiya M, et al. Cervical cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):5119-5137. https://doi.org/10.1002/cncr.30906.
Han K, Milosevic M, Fyles A, et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87(1):111-9. https://doi.org/ 10.1016/j.ijrobp.2013.05.033.
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802-12. https://doi.org/10.1200/JCO.2008.16.4368.
Mileshkin LR, Moore KN, Barnes EH, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):468-482. https://doi.org/10.1016/S1470-2045(23)00147-X/.
Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22-36. https://doi.org/10.1002/ijgo.12611.
Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(1):64-84. https://doi.org/ 10.6004/jnccn.2019.0001.
Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72-iv83. https://doi.org/10.1093/annonc/mdx220.
Gennigens C, De Cuypere M, Hermesse J, et al. Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther. 2021;21(6):657-671. https://doi.org/10.1080/14737140.2021.1879646.
Azria E, Morice P, Haie-Meder C, et al. Results of hysterectomy in patients with bulky residual disease at the end of chemoradiotherapy for stage IB2/II cervical carcinoma. Ann Surg Oncol. 2005;12(4):332-7. https://doi.org/10.1245/ASO.2005.05.020.
Титова В.А. Медицинские аспекты отечественных инновационных технических и технологических возможностей дистанционной и контактной лучевой терапии в онкологии: наука-практическому здравоохранению. Трудный пациент. 2021;19(4):60-64 [Titova VA. Medical aspects of domestic innovative technical and technological capabilities of remote and contact radiation therapy in oncology: Science - practical health care. A Difficult Patient. 2021;19(4):60-64 (In Russ.)]. https://doi.org/ 10.224412/2074-1005-2021-4-60-64.
Кравец О.А., Романова Е.А., Горбунова В.А. Клинические результаты лучевой и химиолучевой терапии местнораспространëнного рака шейки матки. Российский онкологический журнал. 2020;25(3):92-102 [Kravets OA, Romanova EA, Gorbunova VA. Clinical results of radiation and chemoradiation therapy of locally advanced cervix cancer. Russian Journal of Oncology. 2020;25(3):92-102 (In Russ.)]. https://doi.org/ 10.17816/1028-9984-2020-25-3-92-102.
Крейнина Ю.М. Стратегия и тактика лучевой терапии в многокомпонентном лечении местно-распространенного рака шейки матки. Автореф дис. … докт. мед. наук. М. 2011:43 [Kreinina YuM. Strategy and tactics of radiotherapy in multicomponent treatment of locally advanced cervical cancer. Author's thesis. ... doctor of medical sciences. Мoscow. 2011:43 (In Russ.)].
Винокуров В.Л., Жаринов Г.М., Столярова И.В., и др. Результаты локального применения радиомодификаторов при лучевой терапии больных раком шейки матки и тела матки. Медицинская радиология. 1990;9:50 [Vinokurov VL, Zharinov GM, Stolyarova IV, et al. Results of local application of radiomodifiers in radiation therapy for patients with cervical and uterine body cancer. Medical Radiology and Radiation Safety. 1990;9:50 (In Russ.)].
Бойко А.В., Демидова Л.В., Телеус Т.А., и др. Использование радиомодификации для расширения показаний к радикальному лучевому лечению больных с местно распространенными формами рака шейки матки - PDF (Русский). Казанский медицинский журнал. 2000;81(4):287-9 [Boyko AV, Demidova LV, Teleus TA, et al. The use of radiomodification to expand the indications for radical radiation treatment of patients with locally advanced forms of cervical cancer. Kazan Medical Journal. 2000;81(4):287-9 (In Russ.)]. https://doi.org/10.17816/kazmj99852.
Шевченко Л.Н. Лучевая терапия местнораспространенного рака шейки матки в условиях локальной лазериндуцированной гипертермии. Литературный обзор. Вестник РНЦРР. Статья опубликована 12 апреля 2010 года. [Shevchenko L.N. Radiation therapy for the locally advanced cervical carcinoma in the condition of the local laser-induced hyperthermia. Literature review. Vestnik of the Russian Scientific Center of Roentgenoradiology of the Ministry of Healthcare of the Russian Federation. 2010. (In Russ.)]. Available from: http://vestnik.rncrr.ru/vestnik/v10/papers/shevch_v10.htm.
Миндубаев Э.Ю., Насруллаев М.Н., Хасанов Р.Ш., и др. Оптимизация комплексного лечения местно-распространенного рака шейки матки IIb стадии с применением технологии гибридной радиомодификации. Вестник РНЦРР. Статья опубликована 30 ноября 2013 года. [Mindubaev EY, Nasrullaev MN, Hasanov RSh, et al. Stage IIb local cervical cancer complex treatment optimization with the technology of hybrid radiomodification. Vestnik of the Russian Scientific Center of Roentgenoradiology of the Ministry of Healthcare of the Russian Federation. 2013. (In Russ.)]. Available from: http://vestnik.rncrr.ru/vestnik/v13/papers/burmistrov_v13.htm.
Панов А.В., Бурмистров М.В., Зинченко С.В., и др. Метод комбинированной радиомодификации в комплексном лечении местно-распространенного рака шейки матки. Поволжский онкологический вестник. 2014:32-35 [Panov AV, Burmistrov MV, Zinchenko SV, etc. The method of combined radiomodification in the complex treatment of locally advanced cervical cancer. Oncology Bulletin Of The Volga Region. 2014:32-5 (In Russ.)].
Rodionova OG, Gusareva MA, Sheiko EA, et al. Combination ozone therapy as an effective method of radiomodification in chemoradiation treatment of patients with cervical cancer. Journal of Clinical Oncology. 2021;39(15_suppl):17515-17515.
Faye MD, Alfieri J. Advances in radiation oncology for the treatment of cervical cancer. Curr Oncol. 2022;29(2):928-944. https://doi.org/10.3390/curroncol29020079.
Mayadev JS, Ke G, Mahantshetty U, et al. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. Int J Gynecol Cancer. 2022;32(3):436-445. https://doi.org/10.1136/ijgc-2021-003001.
NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer. Version 4.2019 [Internet]. 2019. [cited 08.02.2021]. Available from: https://www2.tri-kobe.org/nccn/guideline/gynecological/english/cervical.pdf.
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43. https://doi.org/10.1056/NEJM199904153401501.
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154-61. https://doi.org/10.1056/NEJM199904153401503.
Katke A, Nanda R, Thejaswini B, et al. Weekly vs. tri-weekly cisplatin based chemoradiation in carcinoma cervix: a prospective randomized study of toxicity and compliance. Rep Pract Oncol Radiother. 2021;26(6):948-954. https://doi.org/10.5603/RPOR.a2021.0115.
Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48. https://doi.org/10.1200/JCO.1999.17.5.1339.
Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606-13. https://doi.org/10.1200/JCO.2000.18.8.1606.
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53. https://doi.org/10.1056/NEJM199904153401502.
Mileshkin LR, Moore KN, Barnes E, et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). J Clin Oncol. 2021;39(Suppl. 18):LBA3.
Gupta S. Adjuvant chemotherapy in locally advanced cervical cancer: the ceiling remains unbroken. J Gynecol Oncol. 2019;30(4):e97. https://doi.org/10.3802/jgo.2019.30.e97.
Lee J, Lin JB, Chang CL, et al. Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes. Gynecol Oncol. 2018;148(2):291-298. https://doi.org/10.1016/j.ygyno.2017.12.003.
Gaffney DK, Jhingran A, Portelance L, et al. Radiation therapy oncology group gynecologic oncology working group: comprehensive results. Int J Gynecol Cancer. 2014;24(5):956-62. https://doi.org/10.1097/IGC.0000000000000135.
Rotman M, Choi K, Guse C, et al. Prophylactic irradiation of the para-aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. Int J Radiat Oncol Biol Phys. 1990;19(3):513-21. https://doi.org/10.1016/0360-3016(90)90475-y.
Wolfson AH, Winter K, Crook W, et al. Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. Int J Radiat Oncol Biol Phys. 2008;70(1):111-7. https://doi.org/10.1016/j.ijrobp.2007.05.069.
Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872-80. https://doi.org/10.1200/JCO.2004.07.197. 197.
Liang JA, Chen SW, Hung YC, et al. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes. Int J Gynecol Cancer. 2014;24(5):901-7. https://doi.org/10.1097/IGC.0b013e31829f4dc5.
Fernandez-Ots A, Crook J. The role of intensity modulated radiotherapy in gynecological radiotherapy: Present and future. Rep Pract Oncol Radiother. 2013;18(6):363-70. https://doi.org/10.1016/j.rpor.2013.08.001.
Jouglar E, Thomas L, de la Rochefordière A, et al. Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes. Cancer Radiother. 2016;20(8):794-800. https://doi.org/10.1016/j.canrad.2016.06.007.
Sapienza LG, Gomes MJL, Calsavara VF, et al. Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials. Gynecol Oncol. 2017;144(2):312-317. https://doi.org/10.1016/j.ygyno.2016.11.044.
Li J, Li Y, Wang H, et al. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer. BMC Cancer. 2023;23(1):51. https://doi.org/10.1186/s12885-023-10517-x.
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer (INTERLACE), Registry name identifier: NCT01566240. ClinicalTrials.gov, 2023. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT01566240 (accessed 2023-08-20).
Han K, Milosevic M, Fyles A, et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87(1):111-9. https://doi.org/10.1016/j.ijrobp.2013.05.033.
Haie-Meder C, Pötter R, Van Limbergen E, et al. Gynaecological (GYN) GEC-ESTRO Working Group. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74(3):235-45. https://doi.org/10.1016/j.radonc.2004.12.015.
Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67-77. https://doi.org/10.1016/j.radonc.2005.11.014.
Hellebust TP, Kirisits C, Berger D, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol. 2010;96(2):153-60. https://doi.org/10.1016/j.radonc.2010.06.004.
Viswanathan AN, Erickson B, Gaffney DK, et al. Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014;90(2):320-8. https://doi.org/10.1016/j.ijrobp.2014.06.005.
Charra-Brunaud C, Harter V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol. 2012;103(3):305-13. https://doi.org/10.1016/j.radonc.2012.04.007.
Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120(3):428-433. https://doi.org/10.1016/j.radonc.2016.03.011.
Pötter R, Tanderup K, Schmid MP, et al. EMBRACE Collaborative Group. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538-547. https://doi.org/10.1016/S1470-2045(20)30753-1.
Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol. 2016;120(3):434-440. https://doi.org/10.1016/j.radonc.2016.03.020.
Pötter R, Tanderup K, Kirisits C, et al. EMBRACE Collaborative Group. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48-60. https://doi.org/10.1016/j.ctro.2018.01.001.
Kagei K, Tokuuye K, Okumura T, et al. Long-term results of proton beam therapy for carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2003;55(5):1265-71. https://doi.org/10.1016/s0360-3016(02)04075-0.
Clivio A, Kluge A, Cozzi L, et al. Intensity modulated proton beam radiation for brachytherapy in patients with cervical carcinoma. Int J Radiat Oncol Biol Phys. 2013;87(5):897-903. https://doi.org/10.1016/j.ijrobp.2013.08.027.
Marnitz S, Wlodarczyk W, Neumann O, et al. Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation - an intraindividual comparison. Radiat Oncol. 2015;10:91. https://doi.org/10.1186/s13014-015-0402-z.
van de Schoot AJ, de Boer P, Crama KF, et al. Dosimetric advantages of proton therapy compared with photon therapy using an adaptive strategy in cervical cancer. Acta Oncol. 2016;55(7):892-9. https://doi.org/10.3109/0284186X.2016.1139179.
Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107(3):267-73. https://doi.org/10.1016/j.radonc.2013.05.007.
Widder J, van der Schaaf A, Lambin P, et al. The quest for evidence for proton therapy: Model-based approach and precision medicine. Int J Radiat Oncol Biol Phys. 2016;95(1):30-36. https://doi.org/10.1016/j.ijrobp.2015.10.004.
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-21. https://doi.org/10.1038/nature12477.
Wang J, Li Z, Gao A, et al. The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. Biomed Pharmacother. 2019;120:109444. https://doi.org/10.1016/j.biopha.2019.109444.
Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services; et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. https://doi.org/10.1038/nature21386.
Liu C, Lu J, Tian H, et al. Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep. 2017;15(3):1063-1070. https://doi.org/10.3892/mmr.2017.6102.
Mezache L, Paniccia B, Nyinawabera A, et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28(12):1594-602. https://doi.org/10.1038/modpathol.2015.108.
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-1867. https://doi.org/10.1056/NEJMoa2112435.
Lorusso D, Xiang Y, Colombo N, et al. 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. Annals of Oncology. 2020;31:1341-2. https://doi.org/10.1016/j.annonc.2020.10.248.
Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28(4):641-655. https://doi.org/10.1097/IGC.0000000000001216.
Verma J, Monk BJ, Wolfson AH. New strategies for multimodality therapy in treating locally advanced cervix cancer. Semin Radiat Oncol. 2016;26(4):344-8. https://doi.org/10.1016/j.semradonc.2016.05.003.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2023